US medical technology company Becton Dickinson opened a plant at the Tatabánya industrial park, west of Budapest, following a HUF 6bn investment. The facility, which will make immunology and cellular biology research reagents used for manufacturing medical products, was financed partly from European Union funds and partly from a government grant. Becton Dickinson Hungary reported a net profit of almost HUF 5bn in the business year ending on Sept. 30, 2016.
